Mechanism of Toxicity in Rotenone Models of Parkinson's Disease

Exposure of rats to the pesticide and complex I inhibitor rotenone reproduces features of Parkinson's disease, including selective nigrostriatal dopaminergic degeneration and α-synuclein-positive cytoplasmic inclusions (Betarbet et al., 2000; Sherer et al., 2003). Here, we examined mechanisms of rotenone toxicity using three model systems. In SK-N-MC human neuroblastoma cells, rotenone (10 nm to 1 μm) caused dose-dependent ATP depletion, oxidative damage, and death. To determine the molecular site of action of rotenone, cells were transfected with the rotenone-insensitive single-subunit NADH dehydrogenase of Saccharomyces cerevisiae (NDI1), which incorporates into the mammalian ETC and acts as a “replacement” for endogenous complex I. In response to rotenone, NDI1-transfected cells did not show mitochondrial impairment, oxidative damage, or death, demonstrating that these effects of rotenone were caused by specific interactions at complex I. Although rotenone caused modest ATP depletion, equivalent ATP loss induced by 2-deoxyglucose was without toxicity, arguing that bioenergetic defects were not responsible for cell death. In contrast, reducing oxidative damage with antioxidants, or by NDI1 transfection, blocked cell death. To determine the relevance of rotenone-induced oxidative damage to dopaminergic neuronal death, we used a chronic midbrain slice culture model. In this system, rotenone caused oxidative damage and dopaminergic neuronal loss, effects blocked by α-tocopherol. Finally, brains from rotenone-treated animals demonstrated oxidative damage, most notably in midbrain and olfactory bulb, dopaminergic regions affected by Parkinson's disease. These results, using three models of increasing complexity, demonstrate the involvement of oxidative damage in rotenone toxicity and support the evaluation of antioxidant therapies for Parkinson's disease.

[1]  H. Forman,et al.  Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity , 2000, The Journal of Biological Chemistry.

[2]  A. Storch,et al.  6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism , 2000, Journal of Neural Transmission.

[3]  Y. Yang,et al.  Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. , 2000, Neuroscience.

[4]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[5]  E. Masliah,et al.  alpha-synuclein promotes mitochondrial deficit and oxidative stress. , 2000, The American journal of pathology.

[6]  C. Marín,et al.  Mitochondria1 respiratory chain activity in skeletal muscle from patients with Parkinson's disease , 1993, Neurology.

[7]  C. Moraes,et al.  Titrating the Effects of Mitochondrial Complex I Impairment in the Cell Physiology* , 1999, The Journal of Biological Chemistry.

[8]  Y. Kagawa,et al.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.

[9]  A. Matsuno-Yagi,et al.  Lack of Complex I Activity in Human Cells Carrying a Mutation in MtDNA-encoded ND4 Subunit Is Corrected by theSaccharomyces cerevisiae NADH-Quinone Oxidoreductase (NDI1) Gene* , 2001, The Journal of Biological Chemistry.

[10]  G. Cohen,et al.  Coupling of Dopamine Oxidation (Monoamine Oxidase Activity) to Glutathione Oxidation Via the Generation of Hydrogen Peroxide in Rat Brain Homogenates , 1981, Journal of neurochemistry.

[11]  M. Zigmond,et al.  Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. , 1996, Advances in Experimental Medicine and Biology.

[12]  Jean Féger,et al.  Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats , 2003, Journal of neurochemistry.

[13]  G. Cohen,et al.  Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione. , 1988, The Journal of pharmacology and experimental therapeutics.

[14]  Y. Yang,et al.  Enhanced vulnerability to oxidative stress by α-synuclein mutations and C-terminal truncation , 2000, Neuroscience.

[15]  Joel S Perlmutter,et al.  Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. , 2002, Archives of neurology.

[16]  R. Nisticò,et al.  The role of oxidative stress in paraquat-induced neurotoxicity in rats: protection by non peptidyl superoxide dismutase mimetic , 2003, Neuroscience Letters.

[17]  E. Masliah,et al.  α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .

[18]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[19]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[20]  Robert Hill,et al.  Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.

[21]  A. Blackburn,et al.  Parkinson's disease, pesticides, and glutathione transferase polymorphisms , 1998, The Lancet.

[22]  M. Beal,et al.  Novel Free Radical Spin Traps Protect against Malonate and MPTP Neurotoxicity , 1999, Experimental Neurology.

[23]  D. Muller,et al.  A simple method for organotypic cultures of nervous tissue , 1991, Journal of Neuroscience Methods.

[24]  D. Eidelberg,et al.  Book Review Movement Disorders: Neurologic principles and practice Edited by Ray L. Watts and William C. Koller. 779 pp., illustrated. New York, McGraw-Hill, 1997. $125. 0-07-035203-8 , 1997 .

[25]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[26]  T. Sherer,et al.  Environment, Mitochondria, and Parkinson's Disease , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[27]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[28]  Todd B. Sherer,et al.  Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.

[29]  C. C. Johnson,et al.  The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.

[30]  C. Fall,et al.  Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. , 1997, Biochimica et biophysica acta.

[31]  A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition. , 2003 .

[32]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[33]  Theodore W Randolph,et al.  Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. , 2003, Biochemistry.

[34]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[35]  R. W. Gracy,et al.  Vitamin E prevents oxidation of antiapoptotic proteins in neuronal cells , 2003, Proteomics.

[36]  E. Tolosa,et al.  Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. , 1993, Neurology.

[37]  A. Lees,et al.  A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.

[38]  T. Flotte,et al.  Use of the NADH-Quinone Oxidoreductase (NDI1) Gene ofSaccharomyces cerevisiae as a Possible Cure for Complex I Defects in Human Cells* , 2000, The Journal of Biological Chemistry.

[39]  A. Schapira,et al.  Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. , 1999, Biochimica et biophysica acta.

[40]  T. Flotte,et al.  A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  M. Vila,et al.  The rotenone model of Parkinson's disease , 2003, Trends in Neurosciences.

[42]  K. Hensley,et al.  Interaction of α‐Phenyl‐N‐tert‐Butyl Nitrone and Alternative Electron Acceptors with Complex I Indicates a Substrate Reduction Site Upstream from the Rotenone Binding Site , 1998, Journal of Neurochemistry.

[43]  A. Murphy,et al.  Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. , 2002, The Biochemical journal.

[44]  S. Shin,et al.  Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. , 2002, The Journal of biological chemistry.

[45]  E. Floor,et al.  Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay , 1998, Journal of neurochemistry.

[46]  J. Tillement,et al.  Nicotine protects rat brain mitochondria against experimental injuries , 2003, Neuropharmacology.

[47]  C. Marsden,et al.  Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease , 2005, Journal of Neural Transmission.

[48]  M. Farrer,et al.  Sensitization of Neuronal Cells to Oxidative Stress with Mutated Human α‐Synuclein , 2000 .

[49]  J. Langston,et al.  Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat , 2002, Neurobiology of Disease.

[50]  M. Farrer,et al.  Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. , 2000, Journal of neurochemistry.

[51]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Roghani,et al.  Neuroprotective effect of vitamin E on the early model of Parkinson’s disease in rat: behavioral and histochemical evidence 1 1 Published on the World Wide Web 3 January 2001. , 2001, Brain Research.

[53]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[54]  W. Schmidt,et al.  Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats , 2002, Behavioural Brain Research.

[55]  P. Jenner,et al.  Oxidative mechanisms in nigral cell death in Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.

[56]  J C Rothwell,et al.  Physiology and Anatomy of Possible Oscillators in the Central Nervous System , 2008, Movement disorders : official journal of the Movement Disorder Society.

[57]  Todd B. Sherer,et al.  An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage , 2002, The Journal of Neuroscience.

[58]  S. Shin,et al.  Formation and Removal of α-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors* , 2002, The Journal of Biological Chemistry.